Research programme: neurotensin receptor 1 modulators - 3B Pharmaceuticals
Latest Information Update: 14 Oct 2016
At a glance
- Originator 3B Pharmaceuticals
- Developer 3B Pharmaceuticals; Ipsen
- Class Imaging agents; Peptide diagnostics; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Neurotensin type 1 receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer